Academic Journal
B15-03 Astegolimab Decreases Exacerbation Risk in Patients With COPD With Frequent Exacerbations, Irrespective of Blood Eosinophil Count: Pooled Analysis of the Pivotal Randomized Trials ALIENTO and ARNASA
| Τίτλος: | B15-03 Astegolimab Decreases Exacerbation Risk in Patients With COPD With Frequent Exacerbations, Irrespective of Blood Eosinophil Count: Pooled Analysis of the Pivotal Randomized Trials ALIENTO and ARNASA |
|---|---|
| Συγγραφείς: | Wedzicha, J A, Agusti, A, Brightling, C E, Calverley, P, Chalmers, J D, Greening, N, Han, M K, Mohan, D, Ng, J, Papi, A, Roche, N, Saenz, R, Samara, K, Tal-Singer, R, Vogelmeier, C F, Yang, X, Celli, B |
| Πηγή: | American Journal of Respiratory and Critical Care Medicine ; volume 212, issue Supplement_1 ; ISSN 1073-449X 1535-4970 |
| Στοιχεία εκδότη: | Oxford University Press (OUP) |
| Έτος έκδοσης: | 2026 |
| Περιγραφή: | Rationale The efficacy and safety of astegolimab (anti-ST2 monoclonal antibody) in patients with COPD with frequent exacerbations were evaluated in two randomized, double-blind, placebo-controlled trials: Phase IIb ALIENTO (NCT05037929) and Phase III ARNASA (NCT05595642). Here, we present results from prespecified pooled analyses of both studies. Methods Both trials randomized patients with COPD (ALIENTO: aged 40-90 years, ARNASA: aged 40-80 years) who were current/former smokers and had a history of frequent exacerbations, regardless of chronic bronchitis or blood eosinophil counts [BEC] 1:1:1 to receive 476 mg astegolimab subcutaneously Q2W or Q4W or placebo, added to optimized maintenance therapy, for a 52-week treatment period. The primary endpoint in both trials was the annualized rate of moderate and severe COPD exacerbations. Key secondary endpoints included proportion of participants with a decrease of ≥ 4 points SGRQ-C total score, annualized rate of severe COPD exacerbations, and safety. Results 2676 participants were included in the pooled modified intent-to-treat (ITT) population (astegolimab Q2W, n = 892; astegolimab Q4W, n = 896; placebo, n = 888). Pooled participant characteristics were generally balanced between arms. Compared with placebo, astegolimab Q2W significantly reduced the rate of moderate and severe COPD exacerbations by 14.7% (Figure; RR 0.853 [95% CI 0.759, 0.959]; P=0.0077); Q4W data are also included in the figure. This exacerbation rate reduction for astegolimab Q2W versus placebo was consistent across prespecified subgroups such as current/former smokers, baseline BEC, and chronic bronchitis. A greater reduction in exacerbation rate with astegolimab Q2W versus placebo was observed in those with a history of > 2 (vs 2) exacerbations, or moderate airflow obstruction (GOLD II) (vs very severe). Compared with placebo, astegolimab Q2W nominally reduced severe exacerbations (32% reduction; RR 0.68 [95% CI 0.52, 0.87]; P=0.0028) and increased the proportion of ... |
| Τύπος εγγράφου: | article in journal/newspaper |
| Γλώσσα: | English |
| DOI: | 10.1093/ajrccm/aamag162.1748 |
| Διαθεσιμότητα: | https://doi.org/10.1093/ajrccm/aamag162.1748 https://academic.oup.com/ajrccm/article-pdf/212/Supplement_1/aamag162.1748/68305793/aamag162.1748.pdf |
| Rights: | https://academic.oup.com/pages/standard-publication-reuse-rights |
| Αριθμός Καταχώρησης: | edsbas.BFC696F |
| Βάση Δεδομένων: | BASE |
| DOI: | 10.1093/ajrccm/aamag162.1748 |
|---|